Insuman Comb 15

Insulin Human, the active ingredient in Insuman Comb 15, is an insulin presented as a subcutaneous preparation for subcutaneous use. It mimics natural pancreatic insulin to lower blood glucose, providing essential therapy for individuals with type 1 diabetes mellitus and type 2 diabetes mellitus who require exogenous insulin to achieve glycaemic control.

GNH USA supplies Insuman Comb 15 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring reliable access to quality‑assured insulin for diabetes management across global markets.

Insuman Comb 15, a human insulin, is used to manage blood glucose levels in diabetes mellitus.

- Type 1 diabetes mellitus: provides basal and prandial insulin coverage to control fasting and post‑meal glucose levels. - Type 2 diabetes mellitus: improves glycaemic control when oral agents or other insulins are insufficient. - Hospitalised hyperglycaemia: used in acute settings to rapidly lower elevated blood glucose.

Insuman Comb 15 may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if meals are missed or dose is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increased caloric storage due to improved glucose utilization. - Edema: fluid retention, particularly in the lower extremities. - Lipodystrophy: changes in subcutaneous fat at repeated injection sites.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypoglycaemia with seizures or loss of consciousness. - Insulin antibody formation that may alter insulin activity. - Hypokalemia: low potassium levels, especially with high insulin doses. - Acute allergic dermatitis: widespread skin rash or hives.

When using Insuman Comb 15, several safety considerations are essential.

- Blood glucose monitoring: adjust dose based on regular glucose readings. - Hypoglycaemia risk: educate patients on recognizing and treating low blood sugar. - Renal impairment: consider dose reduction as insulin clearance may be decreased. - Hepatic dysfunction: use caution, as altered metabolism can affect insulin action. - Concomitant beta‑blockers: may mask hypoglycaemia symptoms, requiring closer observation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 15 can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Sulfonylureas or meglitinides: additive hypoglycaemia risk. - Beta‑blockers: may conceal hypoglycaemia warning signs. - Alcohol: can potentiate insulin‑induced hypoglycaemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may increase blood glucose levels. - Corticosteroids: can raise glucose, requiring dose adjustment. - Oral contraceptives: may affect insulin sensitivity and glucose control.